Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 8 | -1,774 | 445 | 3,514 | -16,352 |
| Depreciation Amortization | -657 | -554 | -394 | -206 | -924 |
| Accounts payable and accrued liabilities | -1,124 | -1,111 | -947 | -725 | 796 |
| Other Working Capital | -964 | -892 | -467 | -1,039 | 2,008 |
| Other Operating Activity | 1,516 | 1,407 | 1,273 | 864 | 2,607 |
| Operating Cash Flow | $-1,221 | $-2,923 | $-90 | $2,408 | $-11,866 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -90 | -80 | N/A | N/A | -13 |
| Purchase Of Investment | -32,864 | -23,135 | -17,538 | -10,790 | -22,902 |
| Sale Of Investment | 35,400 | 24,900 | 18,200 | 6,700 | 36,000 |
| Investing Cash Flow | $2,446 | $1,685 | $663 | $-4,090 | $13,085 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 209 | 209 | 209 | N/A | 405 |
| Other Financing Activity | 0 | 0 | 0 | -8 | 0 |
| Financing Cash Flow | $209 | $209 | $209 | $-8 | $405 |
| Beginning Cash Position | 4,772 | 4,772 | 4,772 | 4,772 | 3,149 |
| End Cash Position | 6,206 | 3,743 | 5,553 | 3,081 | 4,772 |
| Net Cash Flow | $1,434 | $-1,029 | $782 | $-1,690 | $1,623 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,221 | -2,923 | -90 | 2,408 | -11,866 |
| Capital Expenditure | -90 | -80 | N/A | N/A | -13 |
| Free Cash Flow | -1,311 | -3,003 | -90 | 2,408 | -11,879 |